Sign In
Buy NBIX
$175.77
+1.62 (+0.93%)
At Close: Jul 24, 2026
Neurocrine (NBIX) Q4 Earnings: How Key Metrics Compare to Wall Street Estimates
06:31pm, Wednesday, 11'th Feb 2026
While the top- and bottom-line numbers for Neurocrine (NBIX) give a sense of how the business performed in the quarter ended December 2025, it could be worth looking at how some of its key metrics com
Neurocrine Biosciences (NBIX) Lags Q4 Earnings Estimates
06:10pm, Wednesday, 11'th Feb 2026
Neurocrine Biosciences (NBIX) came out with quarterly earnings of $1.88 per share, missing the Zacks Consensus Estimate of $2.25 per share. This compares to earnings of $1 per share a year ago.
Neurocrine Biosciences Reports Fourth-Quarter and Full-Year 2025 Financial Results and Provides Financial Expectations for 2026
04:01pm, Wednesday, 11'th Feb 2026
Total Fourth-Quarter and Full-Year 2025 Net Product Sales of $798.3 Million and $2.83 Billion, Representing Year-Over-Year Growth of 29% and 22%, Respectively INGREZZA® (valbenazine) Full Year 2026 N
Exploring Analyst Estimates for Neurocrine (NBIX) Q4 Earnings, Beyond Revenue and EPS
10:16am, Friday, 06'th Feb 2026
Get a deeper insight into the potential performance of Neurocrine (NBIX) for the quarter ended December 2025 by going beyond Wall Street's top-and-bottom-line estimates and examining the estimates for
Neurocrine Biosciences (NBIX) Reports Next Week: Wall Street Expects Earnings Growth
11:01am, Wednesday, 04'th Feb 2026
Neurocrine (NBIX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Eaton Vance Worldwide Health Sciences Fund Reduces Stake in Novo Nordisk AS by 49.25%
03:01pm, Wednesday, 28'th Jan 2026
Exploring Strategic Moves in the Health Sciences Sector Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) recently submitted its N-PORT filing for
21,000 Shares in Neurocrine Biosciences, Inc. $NBIX Bought by Hussman Strategic Advisors Inc.
05:51am, Wednesday, 28'th Jan 2026
Hussman Strategic Advisors Inc. acquired a new position in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) in the undefined quarter, according to its most recent disclosure with the SEC. The ins
Neurocrine Biosciences Initiates Phase 2 Clinical Study Evaluating NBI-1065890 in Adults with Tardive Dyskinesia
08:30am, Monday, 26'th Jan 2026
SAN DIEGO, Jan. 26, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) today announced the initiation of its Phase 2 clinical study of investigational compound NBI-1065890 in adults with
Can Neurocrine (NBIX) Keep the Earnings Surprise Streak Alive?
01:11pm, Thursday, 22'nd Jan 2026
Neurocrine (NBIX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Neurocrine Biosciences Announces Conference Call and Webcast of Fourth Quarter and Year-End 2025 Financial Results
04:01pm, Wednesday, 21'st Jan 2026
Conference Call and Webcast Scheduled for Wednesday, February 11 SAN DIEGO, Jan. 21, 2026 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its fourth q
INGREZZA showed a nearly two-fold higher VMAT2 occupancy, consistent with greater potency when compared to AUSTEDO XR (deutetrabenazine) after a single dose of each treatment VMAT2 occupancy is a key
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
05:16pm, Monday, 12'th Jan 2026
Neurocrine Biosciences, Inc. (NBIX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Neurocrine Biosciences, Inc. $NBIX Stock Holdings Increased by Robeco Institutional Asset Management B.V.
05:00am, Sunday, 11'th Jan 2026
Robeco Institutional Asset Management B.V. boosted its holdings in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 86.7% in the undefined quarter, according to the company in its most recent
Cerity Partners LLC Acquires 44,852 Shares of Neurocrine Biosciences, Inc. $NBIX
03:22am, Sunday, 11'th Jan 2026
Cerity Partners LLC lifted its stake in shares of Neurocrine Biosciences, Inc. (NASDAQ: NBIX) by 76.3% during the third quarter, according to the company in its most recent filing with the Securities
Pre-Market Stock Futures: The futures are trading lower on Thursday after investors and traders tapped the brakes on the 2026 new year rally, as only the Nasdaq was able to grind out another gain, fin
